Prognostic factors analysis in EGFR mutation‑positive non‑small cell lung cancer with brain metastases treated with whole brain‑radiotherapy and EGFR‑tyrosine kinase inhibitors

Wei,Hangping; Su,Meng; Lin,Ruifang; Li,Huifang; Zou,Changlin

doi:10.3892/ol.2016.4163

Prognostic factors analysis in EGFR mutation‑positive non‑small cell lung cancer with brain metastases treated with whole brain‑radiotherapy and EGFR‑tyrosine kinase inhibitors

Authors:
- Hangping Wei
- Meng Su
- Ruifang Lin
- Huifang Li
- Changlin Zou
View Affiliations

Affiliations: Department of Medical Oncology, Dongyang People's Hospital, Dongyang, Zhejiang 322100, P.R. China, Department of Radiation Oncology and Chemotherapy, The First Affiliated Hospital of Wenzhou Medical University, Wenzhou, Zhejiang 325000, P.R. China
Published online on: January 29, 2016 https://doi.org/10.3892/ol.2016.4163
Pages: 2249-2254

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

The survival time of non‑small cell lung cancer (NSCLC) patients with brain metastases has been previously reported to be 6.5‑10.0 months, even with systematic treatment. Patients that possess a certain epidermal growth factor receptor (EGFR) mutation alongside NSCLC with brain metastases also have a short survival rate, and a reliable prognostic model for these patients demonstrates a strong correlation between the outcome and treatment recommendations. The Cox proportional hazards regression and classification tree models were used to explore the prognostic factors in EGFR mutation‑positive NSCLC patients with brain metastases following whole‑brain radiation therapy (WBRT) and EGFR‑tyrosine kinase inhibitor (EGFR‑TKI) treatment. A total of 66 EGFR mutation‑positive NSCLC patients with brain metastases were retrospectively reviewed. Univariate and multivariate analyses by Cox proportional hazards regression were then performed. The classification tree model was applied in order to identify prognostic groups of the patients. In the survival analysis, age, carcinoembryonic antigen (CEA) and status of the primary tumor were prognostic factors for progression free survival (P=0.006, 0.014 and 0.005, respectively) and overall survival (P=0.009, 0.013 and 0.009, respectively). The classification tree model was subsequently applied, which revealed 3 patient groups with significantly different survival times: Group I, age <65 years and CEA ≤10 µg/ml; Group II, age <65 years and CEA >10 µg/ml or age ≥65 years and CEA ≤10 µg/ml; and Group III, age ≥65 years and CEA >10 µg/ml. The major prognostic predictors for EGFR mutation‑positive NSCLC patients with brain metastases following WBRT and EGFR‑TKI were age and CEA. In addition, primary tumor control may be important for predicting survival.

View Figures

View References

1	Kong DS, Lee JI, Nam DH and Park K, Kim JH, Kim JG, Park JO and Park K: Prognosis of non-small cell lung cancer with synchronous brain metastases treated with gamma knife radiosurgery. J Korean Med Sci. 21:527–532. 2006. View Article : Google Scholar : PubMed/NCBI
2	Zimm S, Wampler GL, Stablein D, Hazra T and Young HF: Intracerebral metastases in solid-tumor patients: Natural history and results of treatment. Cancer. 48:384–394. 1981. View Article : Google Scholar : PubMed/NCBI
3	Yang L, Parkin DM, Ferlay J, Li L and Chen Y: Estimates of cancer incidence in China for 2000 and projections for 2005. Cancer Epidemiol Biomarkers Prev. 14:243–250. 2005.PubMed/NCBI
4	Gaspar L, Scott C, RotmaIl M, Asbell S, Phillips T, Wasserman T, McKenna WG and Byhardt R: Recursive partitioning analysis (RPA) of prognostic factors in three radiation therapy oncology group (RTOG) brain metastases trials. Int J Radiat Oncol Biol Phys. 37:745–751. 1997. View Article : Google Scholar : PubMed/NCBI
5	Lagerwaard FJ, Levendag PC, Nowak PJ, Eijkenboom WM, Hanssens PE and Schmitz PI: Prognostic factors in patients with brain metastases: A review of 1292 patients. Int J Radiat Oncol Biol Phys. 43:795–803. 1999. View Article : Google Scholar : PubMed/NCBI
6	Peng H, Ma M and Han B: Survival analysis of 1,742 patients with stage IV non-small cell lung cancer. Zhongguo Fei Ai Za Zhi. 14:362–366. 2011.(In Chinese). PubMed/NCBI
7	Mekhail T, Sombeck M and Sollaccio R: Adjuvant whole-brain radiotherapy versus observation after radiosurgery or surgical resection of one to three cerebral metastases: Results of the EORTC 22952–26001 study. Curr Oncol Rep. 13:255–258. 2011. View Article : Google Scholar : PubMed/NCBI
8	Pao W, Miller V, Zakowski M, Doherty J, Politi K, Sarkaria I, Singh B, Heelan R, Rusch V, Fulton L, et al: EGF receptor gene mutations are common in lung cancers from ‘never smokers’ and are associated with sensitivity of tumors to gefitinib and erlotinib. Proc Natl Acad Sci USA. 101:13306–13311. 2004. View Article : Google Scholar : PubMed/NCBI
9	Nieder N, Bremnes RM and Andratschke NH: Prognostic scores in patients with brain metastases from non-small cell lung cancer. Thorac Oncol. 4:1337–1341. 2009. View Article : Google Scholar
10	Abacioglu U, Caglar H, Atasoy BM, Abdulloev T, Akgun Z and Kilic T: Gamma knife radiosurgery in non small cell lung cancer patients with brain metastases: Treatment results and prognostic factors. J BUON. 15:274–280. 2010.PubMed/NCBI
11	Yu PJ, Chen WG, Feng QL, Chen W, Jiang MJ and Li ZQ: Association between CYP1B1 gene polymorphisms and risk factors and susceptibility to laryngeal cancer. Med Sci Monit. 21:239–245. 2015. View Article : Google Scholar : PubMed/NCBI
12	Eisenhauer EA, Therasse P, Bogaerts J, Schwartz LH, Sargent D, Ford R, Dancey J, Arbuck S, Gwyther S, Mooney M, et al: New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer. 45:228–247. 2009. View Article : Google Scholar : PubMed/NCBI
13	Gass K, Klein M, Sarnat SE, Winquist A, Darrow LA, Flanders WD, Chang HH, Mulholland JA, Tolbert PE and Strickland MJ: Associations between ambient air pollutant mixtures and pediatric asthma emergency department visits in three cities: A classification and regression tree approach. Environ Health. 14:582015. View Article : Google Scholar : PubMed/NCBI
14	Rovlias A, Theodoropoulos S and Papoutsakis D: Chronic subdural hematoma: Surgical management and outcome in 986 cases: A classification and regression tree approach. Surg Neurol Int. 6:1272015. View Article : Google Scholar : PubMed/NCBI
15	Kong DS, Lee JI, Nam DH and Park K, Kim JH, Kim JG, Park JO and Park K: Prognosis of non-small cell lung cancer with synchronous brain metastases treated with gamma knife radiosurgery. J Korean Med Sci. 21:527–532. 2006. View Article : Google Scholar : PubMed/NCBI
16	Ebert BL, Niemierko E, Shaffe K and Salgia R: Use of temozolomide with other cytotoxic chemotherapy in the treatment of patients with recurrent brain metastases from lung cancer. Oncologist. 8:69–75. 2003. View Article : Google Scholar : PubMed/NCBI
17	Arrieta O, Villarreal-Garza C, Zamora J, Blake-Cerda M, de la Mata MD, Zavala DG, Muñiz-Hernández S and de la Garza J: Long-term survival in patients with non-small cell lung cancer and synchronous brain metastasis treated with whole-brain radiotherapy and thoracic chemoradiation. Radiat Oncol. 6:1662011. View Article : Google Scholar : PubMed/NCBI
18	Ma S, Xu Y, Deng Q and Yu X: Treatment of brain metastasis from non-small cell lung with whole brain radiotherapy and gefitinib in a Chinese population. Lung Cancer. 65:198–203. 2009. View Article : Google Scholar : PubMed/NCBI
19	Lock M, Chow E, Pond GR, Do V, Danjoux C, Dinniwell R, Lea J and Bezjak A: Prognostic factors in brain metastases: Can we determine patients who do not benefit from whole-brain radiotherapy. Clin Oncol (R Coll Radiol). 16:332–338. 2004. View Article : Google Scholar : PubMed/NCBI
20	Xiang Z, Chen J, Zhang H, Shen L and Wei Q: Whole brain radiotherapy-based combined modality treatment of brain metastases from non-small cell lung cancer: A retrospective analysis of prognostic factors. Oncol Res Treat. 38:35–40. 2015. View Article : Google Scholar : PubMed/NCBI
21	Gaspar L, Scott C, Rotman M, Asbell S, Phillips T, Wasserman T, McKenna WG and Byhardt R: Recursive partitioning analysis (RPA) of prognostic factors in three radiation therapy oncology group (RTOG) brain metastases trials. Int J Radiat Oncol Biol Phys. 37:745–51. 1997. View Article : Google Scholar : PubMed/NCBI
22	Gaspar LE, Scott C, Murray K and Curran W: Validation of the RTOG recursive partitioning analysis (RPA) classification for brain metastases. Int J Radiation Oncol Biol Phys. 47:1001–1006. 2000. View Article : Google Scholar
23	Gerosa M, Nicolato A, Foroni R, Tomazzoli L and Bricolo A: Analysis of long-term outcomes and prognostic factors in patients with non-small cell lung cancer brain metastases treated by gamma knife radiosurgery. J Neurosurg. 102(Suppl): 75–80. 2005. View Article : Google Scholar : PubMed/NCBI
24	Zindler JD, Rodrigues G, Haasbeek CJ, De Haan PF, Meijer OW, Slotman BJ and Lagerwaard FJ: The clinical utility of prognostic scoring systems in patients with brain metastases treated with radiosurgery. Radiother Oncol. 106:370–374. 2013. View Article : Google Scholar : PubMed/NCBI
25	Rotin DL, Paklina OV, Kobiakov GL, Shishkina LV, Kravchenko ÉV and Stepanian MA: Lung cancer metastases to the brain: Clinical and morphological prognostic factors. Zh Vopr Neirokhir Im N N Burdenko. 77:24–28. 2013.(In Russian), discussion 29. PubMed/NCBI
26	Rades D, Schild SE, Lohynska R, Veninga T, Stalpers LJ and Dunst J: Two radiation regimens and prognostic factors for brain metastases in non-small cell lung cancer patients. Cancer. 110:1077–1082. 2007. View Article : Google Scholar : PubMed/NCBI
27	Fiala O, Pessek M, Finek J, Benesova L, MinariK M, Bortlicek Z and Topolcan O: Predictive role of CEA and CYFRA21-1 in patients with advanced-stage NSCLC treated with erlotinib. Anticancer Res. 34:3205–3210. 2014.PubMed/NCBI
28	Schilling C, Mortimer D, Dalziel K, Heeley E, Chalmers J and Clarke P: Using Classification and Regression Trees (CART) to identify prescribing thresholds for cardiovascular disease. Pharmacoeconomics. Nov 17–2015.(Epub ahead of print).